Janney Capital Initiates Coverage on Cynapsus Therapeutics Inc(NASDAQ:CYNA). The shares have been rated Buy. The rating by Janney Capital was issued on Jun 15, 2016.
Cynapsus Therapeutics Inc (CYNA) made into the market gainers list on Tuesdays trading session with the shares advancing 3.12% or 0.49 points. Due to strong positive momentum, the stock ended at $16.2, which is also near the day’s high of $16.4999. The stock began the session at $15.99 and the volume stood at 34,547 shares. The 52-week high of the shares is $18.5 and the 52 week low is $10.538. The company has a current market capitalization of $200 M and it has 1,23,16,441 shares in outstanding.
Cynapsus Therapeutics Inc(CYNA) last announced its earnings results on Nov 12, 2015 for Fiscal Year 2015 and Q3.Earnings per share were $0.24.
Cynapsus Therapeutics Inc. is a Canada-based clinical-stage specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinsons disease. The Company’s drug candidate is APL-130277 which is a reformulation of apomorphine. The drug is an approved acute drug in the United States Europe Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson’s disease.